contraindications to glp 1 agonists Clinical Focus on GLP-1 in Type 2 Diabetes Mellitus GLP-1 Receptor Agonists: antidiabetic and

While newly approved pharmacotherapies such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show efficacy, their clinical utility remains constrained by dose-dependent gastrointestinal complications, underscoring the urgent need for safer alternatives

Following the predefined inclusion and exclusion criteria, 36 studies were included in this systematic review and underwent qualitative analysis

The results of the PIONEER-3 trial have now been published in the renowned journal Journal of the American Medical Association (JAMA) and are said to be trend-setting for future therapy of type 2 diabetes.

The inclusion of Akkermansia muciniphilaa microbe studied for its role in gut barrier health and metabolic signalingmakes this formula unique among microbiome supplements